We only have this paper's title and publication details.
Read it at the sourceClinical study reveals IL-17 inflammation in non-responders and B-cell remodeling after daratumumab in refractory immune thrombocytopenia, highlighting mechanisms of therapeutic resistance.
No takes yet. Share an insight, caveat, or question.
Drivet et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: